HAPTOGLOBIN GENOTYPING 

 
 

Cardiovascular Disease: Cardiovascular disease remains the number one cause of death in the United States and will likely become the number one cause of death globally. Current understanding of individual genetic characteristics is improving the ability to treat cardiovascular disorders. The cardiovascular panels offer the opportunity to predict drug response based on a an individual’s DNA.  This allows physicians to treat accordingly, thereby reducing the risk of cardiovascular disease.  

 
 

Diabetes: There are 371 million diabetics worldwide.  By 2035, it is predicted that there will be over 1/2 billion.  Diabetics are at a 50% increased risk of suffering a heart attack or stroke.  Studies have shown that diabetics with two copies of the haptoglobin 2 variant have an increased risk of up to 500%.  MyGenetx offers a proprietary genetic test for haptoglobin 1/2, MyHap2.  People with a personal or family history of diabetes should be tested to evaluate their risk. 

The Journal of  the American College of Cardiology recently published, "Haptoglobin 2-2 Genotyping for Refining Standard Cardiovascular Risk Assessment"

J Am Coll Cardiol. 2015;66(16):1800-1802.doi:10:1016/j.jacc.2015.08.020